An experimental immunotherapy agent was put on the fast track to market approval by US regulators on Monday, after 89 percent of leukemia patients in early trials saw their cancers disappear. The personalized immunotherapy known as CTL019 was developed by the University of Pennsylvania and was designated a "breakthrough therapy" by the US Food and Drug Administration. That means the experimental therapy will benefit from a speedier than average review ...
Read More
No comments:
Post a Comment